POINT Biopharma Global Inc.
Cash in trust
$136M
$135,709,741
Trust per share
$10.00
Redemption value
IPO
Jul 2020
—
Combination deadline
—
Not disclosed
Filings on record
285
Latest Jan 8, 2024
Business combination
- Target
- Not disclosed in an indexed filing
- Announced
- Mar 15, 2021
- Closed
- Jul 1, 2021
Overview
POINT Biopharma Global Inc. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001811764. It completed its initial public offering in Jul 2020. The vehicle is sponsored by Therapeutic through Therapeutic Acquisition Holdings LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.
“we intend to focus on industries that complement our management team's background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare industry, with an emphasis on the biotechnology sector where our management has extensive investment experience.”
Reading the filings
Arithmetic on what POINT Biopharma Global Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.00 per public share, effectively the $10.00 the units were sold at, so little or no interest has accrued to the account yet.
Sponsor promote
The sponsor's founder block is 2,875,000 shares against 12,564,103 public shares, or 18.6% of the combined count, acquired before the IPO at nominal cost. That promote is the structural dilution every public shareholder carries into a combination, and it is why the economics of a de-SPAC differ so sharply from a conventional IPO.
Underwriting
Jefferies led the offering. It has been named on 73 SPAC IPOs, book-running 68 of them, and 53.1% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
285 filings in all. 43 in the last three months, against a busiest month of 34.
News on POINT Biopharma Global Inc.
Last 90 daysNothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.
SEC filing history
Free tier: filings older than 24 hours- 15-12G
Deregistration of securities
Accession 0001193125-24-003853
- EFFECT
Notice of effectiveness
Accession 9999999995-24-000028
- EFFECT
Notice of effectiveness
Accession 9999999995-24-000026
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129777
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129776
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129775
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129773
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129772
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129771
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129770
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129769
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129768
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129767
- 4
Statement of changes in beneficial ownership
Accession 0001104659-23-129766
- SC 13D/A
SC 13D/A
Accession 0001104659-23-129754
- POS AM
POS AM
Accession 0001193125-23-303590
- POS AM
POS AM
Accession 0001193125-23-303584
- S-8 POS
S-8 POS
Accession 0001193125-23-303578
- S-8 POS
S-8 POS
Accession 0001193125-23-303575
- S-8 POS
S-8 POS
Accession 0001193125-23-303570
- 25-NSE
Notification of delisting
Accession 0001354457-23-001006
- 8-K
Termination of a material definitive agreement; Completion of an acquisition; Notice of delisting or failure to satisfy a listing rule
Items 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · Accession 0001193125-23-303512
- SC 14D9/A
SC 14D9/A
Accession 0001193125-23-302270
- SC TO-T/A
SC TO-T/A
Accession 0001193125-23-302265
- 4
Statement of changes in beneficial ownership
Accession 0001193805-23-001635
- SC 13D/A
Amended beneficial ownership report (activist)
Accession 0000921895-23-002787
- SC 14D9/A
SC 14D9/A
Accession 0001193125-23-297130
- SC TO-T/A
SC TO-T/A
Accession 0001193125-23-297093
- SC 14D9/A
SC 14D9/A
Accession 0001193125-23-287946
- SC TO-T/A
SC TO-T/A
Accession 0001193125-23-287939
Pro
Track POINT Biopharma Global Inc. without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
POINT Biopharma Global Inc.: questions answered
What is POINT Biopharma Global Inc.?
POINT Biopharma Global Inc. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001811764. It completed its initial public offering in Jul 2020. The vehicle is sponsored by Therapeutic through Therapeutic Acquisition Holdings LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.
How much does POINT Biopharma Global Inc. hold in trust?
Approximately $135,709,741, or about $10.00 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must POINT Biopharma Global Inc. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if POINT Biopharma Global Inc. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in POINT Biopharma Global Inc., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.00 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for POINT Biopharma Global Inc.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
How much dilution do POINT Biopharma Global Inc.'s founder shares and warrants create?
The founder block is 2,875,000 shares against 12,564,103 public shares, so roughly 18.6% of the combined count sits with the sponsor at nominal cost. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors POINT Biopharma Global Inc., and what is their track record?
Therapeutic Acquisition Holdings LLC is the sponsor entity, part of the Therapeutic franchise. This is the only vehicle we have attributed to that sponsor.
Which banks underwrote the POINT Biopharma Global Inc. IPO?
Jefferies. Jefferies was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is POINT Biopharma Global Inc. a good investment?
That is not a question this site answers. POINT Biopharma Global Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this POINT Biopharma Global Inc. data come from?
Filings POINT Biopharma Global Inc. submitted to the SEC under CIK 0001811764: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Nov 1, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
Therapeutic: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Jefferies in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Healthcare SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All completed de-spac transactions
Business combination closed; the company trades under a new ticker.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.